CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medtide Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medtide Inc
No. 69, 12 Street, Qiantang District
HANGZHOU, ZHJ  China Ticker: 38803880
Business Summary
Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024-----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the board, Chief Executive Officer QiXu 57 5/1/2024 6/11/2020
Executive Director, Joint Company Secretary LingmeiLi 49 5/14/2024 9/1/2023
Executive Director and Chief Business Officer TaoCheng 53 5/14/2024 5/14/2024
6 additional Officers and Directors records available in full report.

General Information
Number of Employees: 522 (As of 12/31/2024)
Outstanding Shares: 141,800,000 (As of 12/31/2024)
Stock Exchange: HKG


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, July 15, 2025